Topic: Papers from the BACR Conference-Response and Resistance in Cancer Therapy

This Special Issue will consist of A Selection of Papers from BACR Conference — Response and Resistance in Cancer Therapy, held in University of Kent, Canterbury, UK, during September 10–12, 2018. Despite substantial improvements in recent decades, the prognosis for those cancer patients who suffer from metastatic disease and depend on systemic drug therapy remains poor. Both intrinsic resistance and the formation of acquired drug resistance substantially affect the efficacy of cancer drugs. The advancement of precision medicine approaches holds promise for both the effective guidance of therapies to patients that will respond and the ability to monitor this tumour response. This will require the successful interpretation of 'omics' data and a close collaboration among pre-clinical researchers, clinicians, and computational biologists in both academia and industry to develop these strategies. This conference will bring together and showcase cancer researchers from these areas, who will present and discuss the latest advances in understanding the mechanisms of drug resistance in cancer, the identification of biomarkers of drug sensitivity/resistance and how they can be linked to precision medicine approaches. This Special Issue will cover new and novel areas of research pertaining to cancer drug resistance presented at this conference and therefore will represent state-of-the-art and up-to-date coverage of progress.

Cancer drug resistance, prognosis, systemic drug therapy, intrinsic resistance, precision medicine, tumour response, mechanism, bio-marker

20 Feb 2019